Rising costs may not be a result of orphan drugs

Published Online: Sep 12,2016 Laurie Toich, Assistant Editor From Daraprim’s price rising 5556% by Turing Pharmaceuticals under the leadership of Martin Shkreli, to the most recent pricing scandal with Mylan’s EpiPen, Americans have been faced with high out-of-pocket costs for many prescription drugs. Government institutions, such as the US Centers for Medicare and Medicaid, have begun crafting novel ways to reduce …

Why orphan drugs are a key part of pharma’s future?

Back in the 1980's when the Orphan Drug Act was created, legislators, government agencies and even industry weren't expecting that it would create a multi-billion dollar market where companies now fight fiercely for a share in this segment. It's also understood that the timing of the Act was very fortuitous as it was closely aligned with the beginning of US' …

Europe’s reaction to CAVOMP’s harmonization in the orphan drugs space

There are conflicting opinions about CAVOMP and how far it will go with harmonizing reimbursement policies among the 27 countries in the EU. We need to remember that sovereignty issues to consider as well. Governments, the EMA, industry, payers and patients, all feel that more collaboration is necessary in order to align everyone's interests. It may also be necessary to …

How to bring an orphan drug to market – why is there legislation for rare diseases?

Orphan drugs trainer Elizabeth Hernberg-StÃ¥hl looks at why there is legislation for drugs for rare diseases in this video extract. She discusses the Orphan Drug Act of 1983 and looks at the driving forces behind its introduction, as well as how it has helped to stimulate the orphan drugs industry since. To find out more about the orphan drugs industry …